3-(2-formamidoethyl)thiophene | 28783-48-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 3-(2-formamidoethyl)thiophene
• 英文别名: N-(2-(thiophen-3-yl)ethyl)formamide；thien-3-ylethyl formamide；3-thienylethyl formamide；N-(2-thiophen-3-ylethyl)formamide
• CAS: 28783-48-4
• 化学式: C₇H₉NOS
• 分子量: 155.221
• InChiKey: GXGGHYDFSKCLPX-UHFFFAOYSA-N

物化性质

• 沸点：
  353.4±25.0 °C(Predicted)
• 密度：
  1.155±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  57.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-formamidoethyl)thiophene 在 sodium tetrahydroborate 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 7.0h， 生成 叔-丁基4,5-二氢噻吩并[2,3-C]吡啶-6(7H)-羧酸酯
  参考文献：
  名称：

  Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy

  摘要：

  KCNQ (Kv7) has emerged as a validated target for the development of novel anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives were designed, synthesized and evaluated as KCNQ openers for the treatment of epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro and in vivo. Several compounds were found to be potent KCNQ openers. Compound 1 with favorable in vitro activity was submitted to evaluation in vivo. Results showed that compound 1 owned significant anti-convulsant activity with no adverse effects. It was also found to posses favorable pharmacokinetic profiles in rat. This research may provide novel potent compounds for the discovery of KCNQ openers in treating epilepsy.

  DOI：

  10.1016/j.bmcl.2018.05.019
• 作为产物：
  描述：

  3-噻吩乙腈 在 borane-dimethyl sulfide complex 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 19.33h， 生成 3-(2-formamidoethyl)thiophene
  参考文献：
  名称：

  作为钾通道调节剂的化合物

  摘要：

  本发明涉及一类作为钾通道调节剂的化合物，其为式(I)化合物或其药学上可接受的盐，所述化合物或其药学上可接受的盐对治疗和预防受钾离子通道的活性影响的疾病和病症有效果。

  公开号：

  CN108250128A

文献信息

• [EN] MU OPIOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DU RÉCEPTEUR OPIOÏDE DE TYPE MU
  申请人：UNIV CALIFORNIA

  公开号：WO2018129393A1

  公开（公告）日：2018-07-12

  Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

  本文描述了用于调节μ阿片受体活性的组合物和方法。
• Thieno[2,3-O]azepine compounds and CNS affecting use thereof
  申请人：Lilly Industries Limited

  公开号：US04904653A1

  公开（公告）日：1990-02-27

  Compounds of the formula ##STR1## in which R.sup.1 is hydrogen, hydroxy, nitro, cyano, halo, amino, acetamido, hydroxy-C.sub.1-4 alkyl, carboxaldehydo, C.sub.1-4 alkylcarbonyl, carboxy, C.sub.1-4 alkoxy-carbonyl, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulphonyl or C.sub.1-4 alkoxy-C.sub.1-4 alkyl, R.sup.2 is hydrogen, hydroxy, nitro, cyano, halo, amino, carboxamido, acetamido, hydroxy-C.sub.1-4 alkyl, carboxyaldehydo, C.sub.1-4 alkylcarbonyl, carboxy, C.sub.1-4 alkoxycarbonyl, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulphonyl, C.sub.1-4 alkoxy-C.sub.1-4 alkyl, oximino or aminomethyl, R.sup.3 is optionally substituted phenyl or optionally substituted phenyl ortho condensed with an optionally substituted ring selected from benzene, cyclohexane, cyclohexene, cyclopentane or cyclopentene, in which ring one of the carbon atoms may be replaced by oxygen, sulphur or nitrogen, and R.sup.4 is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or optionally substituted benzyl; and salts thereof; have central nervous system activity.

  公式为##STR1##的化合物，其中R.sup.1是氢、羟基、硝基、氰基、卤素、氨基、乙酰胺基、羟基-C.sub.1-4烷基、羧醛基、C.sub.1-4烷基羰基、羧基、C.sub.1-4烷氧羰基、C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.1-4烷硫基、C.sub.1-4烷基磺酰基或C.sub.1-4烷氧基-C.sub.1-4烷基，R.sup.2是氢、羟基、硝基、氰基、卤素、氨基、羧胺基、乙酰胺基、羟基-C.sub.1-4烷基、羧醛基、C.sub.1-4烷基羰基、羧基、C.sub.1-4烷氧基羰基、C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.1-4烷硫基、C.sub.1-4烷基磺酰基、C.sub.1-4烷氧基-C.sub.1-4烷基、肟基或氨基甲基，R.sup.3是可选择取代的苯基或可选择取代的苯基与苯、环己烷、环己烯、环戊烷或环戊烯中的可选择取代的环之一发生邻位缩合，在该环中碳原子之一可被氧、硫或氮取代，R.sup.4是氢、C.sub.1-4烷基、C.sub.2-4烯烃基或可选择取代的苄基；以及其盐；具有中枢神经系统活性。
• Pharmaceutical compounds
  申请人：Lilly Industries Limited

  公开号：US05028602A1

  公开（公告）日：1991-07-02

  Pharmaceutical compounds having the formula ##STR1## in which R.sup.1 is hydrogen, hydroxy, nitro, cyano, halo, amino, acetamido, hydroxy-C.sub.1-4 alkyl, carboxaldehydo, C.sub.1-4 alkyl-carbonyl, carboxy, C.sub.1-4 alkoxy-carbonyl, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulphonyl or C.sub.1-4 alkoxy-C.sub.1-4 alkyl, R.sup.2 is hydrogen or halo, R.sup.3 is optionally substituted phenyl or optionally substituted phenyl ortho condensed with an optionally substituted ring selected from benzene, cyclohexane, cyclohexene, cyclopentane or cyclopentene, in which ring one of the carbon atoms may be replaced by oxygen, sulphur or nitrogen, and R.sup.4 is hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or optionally substituted benzyl; and salts thereof.

  具有以下结构式的药物化合物##STR1##其中R.sup.1是氢、羟基、硝基、氰基、卤素、氨基、乙酰氨基、羟基-C.sub.1-4烷基、羧醛基、C.sub.1-4烷基-羰基、羧基、C.sub.1-4烷氧羰基、C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.1-4烷基硫基、C.sub.1-4烷基磺酰基或C.sub.1-4烷氧基-C.sub.1-4烷基，R.sup.2是氢或卤素，R.sup.3是可选取代的苯基或可选取代的苯基与苯环、环己烷、环己烯、环戊烷或环戊烯中的可选取代的环之一发生邻位缩合，其中环中的一个碳原子可以被氧、硫或氮取代，R.sup.4是氢、C.sub.1-4烷基、C.sub.2-4烯基或可选取代的苄基；以及其盐。
• Aza-Substituted Spiro Derivatives
  申请人：Jitsuoka Makoto

  公开号：US20090258871A1

  公开（公告）日：2009-10-15

  A compound of the following formula (I) or its pharmaceutically-acceptable salt is provided: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH 2 )m 2 -, —O— or the like, and m2 represents 0 or 1; Q represents a methine group or a nitrogen atom; and R represents a group represented by the following formula (II-1) (wherein R 6 , R 7 and R 8 independently represent a lower alkyl group or the like].

  提供以下式子（I）的化合物或其药学上可接受的盐：[其中X、Y、Z和W各自独立地表示甲基基团或氮原子，前提是当X、Y、Z和W全部为甲基基团时；A表示—O—或类似物，B表示—C（O）—或类似物，D表示—（CH2）m2-、—O—或类似物，m2表示0或1；Q表示甲基基团或氮原子；R表示由以下式子（II-1）表示的基团（其中R6、R7和R8各自独立地表示较低的烷基基团或类似物）。
• Antithrombotic Diamides
  申请人：Franciskovich Jeffry Bernard

  公开号：US20090062271A1

  公开（公告）日：2009-03-05

  This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

  本申请涉及公式I化合物（或其药学上可接受的盐），其制药组合物，以及其作为Xa因子和/或凝血酶抑制剂的用途，以及其制备过程和中间体。